Figure 6. Antiphospholipid antibody–mediated thrombosis is dependent upon neutrophil PSGL-1 and can be mitigated by anti-PSGL-1 therapy.

(A) PSGL-1^–/– mice were treated with control or APS IgG (specifically APS 1 as in Figure 4). At the time of flow restriction in the inferior vena cava, mice were administered WT or PSGL-1^–/– neutrophils by i.v. injection. Thrombus length was measured 6 hours later. The mean for each group is denoted by a horizontal line, while each data point represents an individual mouse; *P < 0.05 adjusted using Kruskal-Wallis test followed by Dunn’s multiple comparisons test. (B) WT mice were treated with APS IgG. Twenty-four hours before flow restriction, mice were also administered a single dose of either anti–PSGL-1 or isotype control antibody. Thrombus length was measured 6 hours after flow restriction. The mean for each group is denoted by a horizontal line, while each data point represents an individual mouse; *P < 0.05 by Mann-Whitney test.